RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the Phase 2 trial of RP-A501 for Danon disease, particularly concerning the safety and clinical trial protocol [3]. - It is claimed that the company failed to disclose serious adverse events, including participant deaths, and made significant protocol amendments without informing investors [3][4]. Group 2: Impact on Stock - Following the announcement of a clinical hold by the U.S. Food and Drug Administration on May 27, 2025, due to serious adverse events, Rocket Pharmaceuticals' stock price experienced a decline [4]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff in the lawsuit, with the lead plaintiff representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for the litigation, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].